Evaluation of prophylactic enoxaparin sodium in the prevention of venous thromboembolism after gynecological laparoscopic surgery

Evaluation of prophylactic enoxaparin sodium in the prevention of venous thromboembolism after gynecological laparoscopic surgery - Enoxaparin sodium in gynecological laparoscopy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008273

Enrollment

100

Registered

2012-07-31

Start date

2012-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

benign gynecological disease

Interventions

administration of enoxaparin sodium control (without enoxaparin sodium)

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: women undergoing laparoscopic surgery for benign gynecological disease

Exclusion criteria

Exclusion criteria: allergy to heparin or related products bleeding symptom acute bacterial endocarditis history of heparin related thrombocytopenia renal failure bodyweight less than 40kg any clinical signs of VTE at screening or within 1 year before surgery systemic chemo-therapy within 3 weeks before surgery radiation therapy within 15 days before surgery spinal or epidural anesthesia

Design outcomes

Primary

Measure	Time frame
development of VTE after surgery	—

Countries

Japan

Contacts

Public ContactMichio Kitjaima

Nagasaki University Department of Obstetrics and Gynecology

m-kita@nagasaki-u.ac.jp095-819-7363

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026